OpenAI partners with Novo Nordisk to speed up drug discovery and delivery

Artificial intelligence powerhouse OpenAI Group PBC is lending its expertise to Novo Nordisk A/S in a brand new partnership announced today that goals to speed up research within the pharmaceutical industry.

The sweeping collaboration will see OpenAI’s intelligent agents embedded across the drug maker’s workflows so as to enhance every thing from lab-based drug discovery to the complexities of business distribution.

Under the partnership, Novo Nordisk will gain access to OpenAI’s most advanced frontier models. Its goal is to empower its workforce to work smarter and faster by utilizing AI to crunch through massive datasets that bathroom down human researchers for weeks, and automate other laborious tasks across its business.

Novo Nordisk said the collaboration will help it overcome one of the crucial pressing challenges facing the life sciences industry: the sheer volume of biological data it has to take care of. The drug company makes a speciality of creating medicines for chronic illnesses comparable to obesity and diabetes, but the problem of identifying essentially the most promising molecules for more practical treatments is a multiyear process that costs billions of dollars.

By utilizing AI to hurry up the strategy of finding hidden patterns inside genomic, biological and clinical trial datasets, the corporate hopes to shorten these development cycles dramatically. The concept is to make use of AI to simulate experiments that will normally should be performed in labs, so it will possibly predict the efficacy of medication before a physical sample is even created.

Novo Nordisk President and Chief Executive Mike Doustdar said tens of millions of individuals globally living with chronic illnesses are waiting for brand spanking new therapies to be discovered that may change their lives. “Integrating AI in our on a regular basis work gives us the power to research datasets at a scale that was previously inconceivable,” he said. “We will discover patterns we couldn’t see and test hypotheses faster than ever. This implies discovering recent therapies and bringing them to market faster than ever before.”

The businesses stressed that that is greater than only a software deal. OpenAI will work directly with Novo Nordisk’s employees to show them how one can make essentially the most out of its AI technologies. The goal is to reinforce their level of “AI literacy” in order that every department can construct and use custom tools.

Besides using AI to research datasets to try to discover essentially the most promising drug candidates, Novo Nordisk can even apply the technology to its manufacturing, supply chain and distribution operations to attempt to speed up the time it takes to get its medicines into the hands of patients. To be sure that AI-based decisions remain ethical and accurate, the 2 firms said they are going to create a strict data governance framework that features human oversight.

The partnership will kick off with a series of pilot programs across Novo Nordisk’s research, development and manufacturing operations. If successful, these projects will pave the best way for OpenAI’s models to be integrated with its entire global operations by the top of the 12 months.

OpenAI CEO Sam Altman said the goal is to assist people live higher and longer lives. “This collaboration with Novo Nordisk will help them to speed up scientific discovery, run smarter global operations and redefine the longer term of patient care,” he said.

Image: SiliconANGLE/Dreamina